{"id":"finerenone-bay94-8862","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hyperkalemia"},{"rate":"1-3","effect":"Hyponatremia"},{"rate":"5-10","effect":"Increased serum creatinine"},{"rate":"5-8","effect":"Diarrhea"},{"rate":"3-5","effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL2181927","moleculeType":"Small molecule","molecularWeight":"378.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Finerenone selectively antagonizes the mineralocorticoid receptor (MR), a ligand-activated transcription factor activated by aldosterone. By blocking MR, it reduces pathological inflammation, oxidative stress, and fibrosis in renal and cardiac tissues. This mechanism provides cardio-renal protective effects beyond traditional blood pressure reduction, particularly in patients with chronic kidney disease and diabetes.","oneSentence":"Finerenone is a non-steroidal mineralocorticoid receptor antagonist that blocks aldosterone signaling to reduce inflammation and fibrosis in the kidneys and cardiovascular system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:36.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease in patients with type 2 diabetes"},{"name":"Diabetic kidney disease"}]},"trialDetails":[{"nctId":"NCT05348733","phase":"","title":"A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-06-13","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":4500},{"nctId":"NCT07192952","phase":"PHASE3","title":"A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-06-01","conditions":"Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)","enrollment":117},{"nctId":"NCT05457283","phase":"PHASE3","title":"A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-11-08","conditions":"Chronic Kidney Disease, Proteinuria, Children","enrollment":100},{"nctId":"NCT07188805","phase":"PHASE3","title":"A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-11-19","conditions":"Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)","enrollment":111},{"nctId":"NCT07232537","phase":"","title":"An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-11-20","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":500},{"nctId":"NCT06763146","phase":"","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-09-22","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":1200},{"nctId":"NCT07124039","phase":"","title":"An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-07-16","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":5000},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07442448","phase":"PHASE4","title":"Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"Cathay General Hospital","startDate":"2026-04","conditions":"Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction","enrollment":40},{"nctId":"NCT06008197","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients","status":"RECRUITING","sponsor":"Colorado Prevention Center","startDate":"2024-01-17","conditions":"Heart Failure, Acute Heart Failure","enrollment":5200},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT05047263","phase":"PHASE3","title":"A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-09-21","conditions":"Non-diabetic Chronic Kidney Disease","enrollment":1584},{"nctId":"NCT07397650","phase":"PHASE4","title":"Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure","status":"RECRUITING","sponsor":"Juntendo University","startDate":"2026-02","conditions":"Acute Heart Failure","enrollment":550},{"nctId":"NCT05196035","phase":"PHASE3","title":"A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-03-28","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":219},{"nctId":"NCT07379840","phase":"","title":"A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-12-23","conditions":"Chronic Heart Failure","enrollment":300},{"nctId":"NCT07270172","phase":"","title":"The MICRON Study - A Steno 1 Substudy","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-10-27","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT07351864","phase":"PHASE4","title":"Finerenone Plus SGLT2 Inhibitors in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-18","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT07348718","phase":"","title":"Rubix LS Diabetic Kidney Disease (DKD) Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rubix LS","startDate":"2025-12-15","conditions":"Diabetic Kidney Disease (DKD)","enrollment":2000},{"nctId":"NCT06278207","phase":"","title":"An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-05-15","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":50000},{"nctId":"NCT07326631","phase":"NA","title":"Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"College of Physicians and Surgeons Pakistan","startDate":"2026-01-01","conditions":"Diabetic Kidney Disease (DKD), Heart Failure","enrollment":120},{"nctId":"NCT07315191","phase":"PHASE4","title":"Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","status":"RECRUITING","sponsor":"Capital Institute of Pediatrics, China","startDate":"2025-06-13","conditions":"Henoch Schönlein Purpura Nephritis","enrollment":116},{"nctId":"NCT06954090","phase":"PHASE4","title":"Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study","status":"ENROLLING_BY_INVITATION","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2025-11-20","conditions":"Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria","enrollment":50},{"nctId":"NCT06058585","phase":"PHASE3","title":"The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-04","conditions":"Chronic Kidney Diseases","enrollment":1000},{"nctId":"NCT06818305","phase":"PHASE2","title":"Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT","status":"TERMINATED","sponsor":"Jinling Hospital, China","startDate":"2025-01-01","conditions":"Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy","enrollment":10},{"nctId":"NCT07270367","phase":"PHASE3","title":"Finerenone and Cardiac Remodeling","status":"NOT_YET_RECRUITING","sponsor":"Subodh Verma","startDate":"2025-12","conditions":"Heart Failure","enrollment":156},{"nctId":"NCT07239570","phase":"PHASE4","title":"A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Peter Rossing","startDate":"2025-06-20","conditions":"Chronic Kidney Disease(CKD)","enrollment":125},{"nctId":"NCT07235891","phase":"PHASE4","title":"Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-11-20","conditions":"Retinal Nerve Fiber Layer Thickness, Chronic Kidney Disease","enrollment":40},{"nctId":"NCT06608212","phase":"","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-10-09","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":150000},{"nctId":"NCT05901831","phase":"PHASE3","title":"A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-02-26","conditions":"Chronic Kidney Disease, Type 1 Diabetes Mellitus","enrollment":241},{"nctId":"NCT07181135","phase":"PHASE3","title":"FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-12-01","conditions":"Chronic Kidney Disease","enrollment":180},{"nctId":"NCT06381323","phase":"PHASE4","title":"The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist","enrollment":55},{"nctId":"NCT07155694","phase":"PHASE4","title":"Role of Finerenone in African American Veterans With Diabetic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Washington D.C. Veterans Affairs Medical Center","startDate":"2025-09","conditions":"Diabetic Kidney Disease","enrollment":30},{"nctId":"NCT04435626","phase":"PHASE3","title":"Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-09-14","conditions":"Heart Failure","enrollment":6016},{"nctId":"NCT05552339","phase":"","title":"A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-08-18","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":5000},{"nctId":"NCT07116512","phase":"PHASE1","title":"A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-05-02","conditions":"Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers","enrollment":60},{"nctId":"NCT05705271","phase":"PHASE4","title":"A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-02-08","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT07056595","phase":"NA","title":"Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","status":"RECRUITING","sponsor":"Botkin Hospital","startDate":"2025-05-21","conditions":"IgA Nephropathy (IgAN)","enrollment":30},{"nctId":"NCT07026539","phase":"PHASE4","title":"Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-10-23","conditions":"Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT06143566","phase":"PHASE1, PHASE2","title":"Polypill for Prevention of Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-11","conditions":"Type 2 Diabetes, High Blood Pressure","enrollment":200},{"nctId":"NCT06244758","phase":"PHASE3","title":"Finerenone and Renal Oxidative Stress","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2024-01-18","conditions":"Type2diabetes","enrollment":75},{"nctId":"NCT06059664","phase":"PHASE2","title":"The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-04-23","conditions":"Kidney Transplant; Complications","enrollment":150},{"nctId":"NCT06906081","phase":"PHASE2","title":"Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study","status":"RECRUITING","sponsor":"Peter Rossing","startDate":"2025-05-02","conditions":"Cardiovascular Autonomic Neuropathy, Type 2 Diabetes, Diabetic Neuropathies","enrollment":100},{"nctId":"NCT06838416","phase":"","title":"Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-11-17","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Renal Function","enrollment":300},{"nctId":"NCT06835322","phase":"PHASE2","title":"Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-20","conditions":"Glomerulonephritis","enrollment":100},{"nctId":"NCT05254002","phase":"PHASE2","title":"A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-06-23","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":1664},{"nctId":"NCT06033950","phase":"PHASE3","title":"A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists","status":"RECRUITING","sponsor":"Colorado Prevention Center","startDate":"2024-08-20","conditions":"Heart Failure","enrollment":2600},{"nctId":"NCT06024746","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)","status":"RECRUITING","sponsor":"Colorado Prevention Center","startDate":"2024-07-09","conditions":"Heart Failure","enrollment":1500},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT06727409","phase":"PHASE4","title":"Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-12-12","conditions":"Patients With Type 2 Diabetes","enrollment":82},{"nctId":"NCT06655480","phase":"PHASE2","title":"Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2025-03-18","conditions":"HFpEF, LVDD, Myocardial Fibrosis","enrollment":50},{"nctId":"NCT06082063","phase":"PHASE3","title":"Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes","status":"RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-07-01","conditions":"Cardiovascular Diseases, Heart Failure, Type 1 Diabetes","enrollment":2000},{"nctId":"NCT05703880","phase":"","title":"An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-06-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":15948},{"nctId":"NCT05526157","phase":"","title":"An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-10-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":50000},{"nctId":"NCT05897372","phase":"PHASE2","title":"Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","status":"TERMINATED","sponsor":"Iain Bressendorff","startDate":"2023-08-01","conditions":"Diabetic Kidney Disease","enrollment":1},{"nctId":"NCT06457074","phase":"PHASE4","title":"Finerenone for Patients With Primary Aldosteronism (FAIRY)","status":"RECRUITING","sponsor":"Qifu Li","startDate":"2024-06-04","conditions":"Primary Aldosteronism","enrollment":306},{"nctId":"NCT06580288","phase":"PHASE3","title":"Effect of Finerenone in IgA Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2024-10-08","conditions":"IgA Nephropathy","enrollment":120},{"nctId":"NCT06573411","phase":"PHASE4","title":"Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-09-30","conditions":"Primary Membranous Nephropathy","enrollment":88},{"nctId":"NCT05924620","phase":"PHASE4","title":"Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2023-06-21","conditions":"Primary Aldosteronism","enrollment":60},{"nctId":"NCT06460987","phase":"","title":"Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy","status":"COMPLETED","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2022-12-01","conditions":"Finerenone, IgA Nephropathy, Proteinuria","enrollment":245},{"nctId":"NCT06301022","phase":"","title":"Effectiveness and Safety of Finerenone in Chinese CKD Patients Without Diabetes Mellitus","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2022-12-15","conditions":"Chronic Kidney Diseases","enrollment":90},{"nctId":"NCT05887817","phase":"PHASE4","title":"Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saga University","startDate":"2023-09-07","conditions":"Type 2 Diabetes, Chronic Kidney Diseases","enrollment":100},{"nctId":"NCT05640180","phase":"","title":"An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-11-23","conditions":"Chronic Kidney Disease, Type 2 Diabetes","enrollment":17847},{"nctId":"NCT06164379","phase":"PHASE4","title":"Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-12-16","conditions":"Primary Aldosteronism","enrollment":150},{"nctId":"NCT05013008","phase":"PHASE2","title":"An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-08-18","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":951},{"nctId":"NCT05974566","phase":"","title":"Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2023-08-01","conditions":"Heart Failure With Reduced Ejection Fraction, Diabetes Mellitus, Diabetic Nephropathies","enrollment":60},{"nctId":"NCT02540993","phase":"PHASE3","title":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-17","conditions":"Chronic Kidney Disease","enrollment":5734},{"nctId":"NCT05814770","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-05","conditions":"Primary Aldosteronism, Hypertension","enrollment":96},{"nctId":"NCT05688579","phase":"PHASE4","title":"Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia","status":"ENROLLING_BY_INVITATION","sponsor":"Nanfang Li","startDate":"2023-04-16","conditions":"Hypertension, Hyperaldosteronaemia","enrollment":8000},{"nctId":"NCT04795726","phase":"NA","title":"A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-03-10","conditions":"Diabetic Retinopathy","enrollment":70},{"nctId":"NCT04477707","phase":"","title":"A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-07-23","conditions":"Diabetic Retinopathy","enrollment":206},{"nctId":"NCT02545049","phase":"PHASE3","title":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-17","conditions":"Diabetic Kidney Disease","enrollment":7352},{"nctId":"NCT01345656","phase":"PHASE2","title":"BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05-09","conditions":"Heart Failure","enrollment":457},{"nctId":"NCT01473108","phase":"PHASE1","title":"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03-29","conditions":"Clinical Pharmacology","enrollment":67},{"nctId":"NCT01687920","phase":"PHASE1","title":"Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09-17","conditions":"Heart Failure","enrollment":25},{"nctId":"NCT04908436","phase":"PHASE1","title":"A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-10-27","conditions":"Worsening Chronic Heart Failure, Chronic Kidney Disease","enrollment":33},{"nctId":"NCT01955694","phase":"PHASE2","title":"Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-11","conditions":"Heart Failure","enrollment":72},{"nctId":"NCT04881994","phase":"PHASE1","title":"A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-25","conditions":"Worsening Chronic Heart Failure, Diabetic Nephropathy","enrollment":27},{"nctId":"NCT01968668","phase":"PHASE2","title":"Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Diabetic Nephropathies","enrollment":96},{"nctId":"NCT01807221","phase":"PHASE2","title":"Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-06-17","conditions":"Heart Failure","enrollment":1066},{"nctId":"NCT01874431","phase":"PHASE2","title":"Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-06-12","conditions":"Diabetic Nephropathies","enrollment":823},{"nctId":"NCT02956109","phase":"PHASE1","title":"Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-16","conditions":"Pharmacokinetics","enrollment":16},{"nctId":"NCT02957396","phase":"PHASE1","title":"Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-17","conditions":"Pharmacokinetics","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Finerenone (BAY94-8862)","genericName":"Finerenone (BAY94-8862)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Finerenone is a non-steroidal mineralocorticoid receptor antagonist that blocks aldosterone signaling to reduce inflammation and fibrosis in the kidneys and cardiovascular system. Used for Chronic kidney disease in patients with type 2 diabetes, Diabetic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}